Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hisamitsu Pharmaceutical CoFSE:4530 89 EV-to-EBIT is 13.17 as of Jul. 24, 2026, which is 13% above its 10-year median of 11.63. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 690 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 56.96% on this metric.
Hisamitsu Pharmaceutical Co (FSE:4530) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hisamitsu Pharmaceutical Co's Enterprise Value for the quarter that ended in Nov. 2025 was 円172,740 Mil.
Hisamitsu Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円23,677 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co EV-to-EBIT Related Terms
Hisamitsu Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSE:4530 vs ESPR, AMPH, ETON: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's EV-to-EBIT falls into.
Hisamitsu Pharmaceutical Co's current Enterprise Value is 円311,836 Mil.
Hisamitsu Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円23,677 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (FSE:4530) has a EV-to-EBIT of 13.17 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is 13% above median its historical median of 11.63. Over the past decade, Hisamitsu Pharmaceutical Co's EV-to-EBIT has ranged from 6.53 to 26.66. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #297 out of 690 companies in the Drug Manufacturers industry, placing it in the top 43%.
Is Hisamitsu Pharmaceutical Co's EV-to-EBIT too high?
Hisamitsu Pharmaceutical Co's current EV-to-EBIT of 13.17 is 13% above median its 10-year median of 11.63. Over the past 10 years, this metric has ranged from a low of 6.53 to a high of 26.66. The Drug Manufacturers industry median EV-to-EBIT is 15.46. Hisamitsu Pharmaceutical Co's value of 13.17 is 14.8% below this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #297 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's EV-to-EBIT compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #297 out of 690 companies for EV-to-EBIT. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBIT is 15.46. Hisamitsu Pharmaceutical Co's value of 13.17 is 14.8% below this benchmark. Historically, Hisamitsu Pharmaceutical Co's own EV-to-EBIT has ranged from 6.53 to 26.66 over the past decade. While the company's 10-year median is 11.63 vs. the industry median of 15.46, Hisamitsu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current EV-to-EBIT of 13.17 is 14.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current EV-to-EBIT is 13.17, which is 13% above median its own 10-year median of 11.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current EV-to-EBIT of 13.17. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current EV-to-EBIT is 13.17, which is 13% above median its 10-year median of 11.63 and 14.8% below the Drug Manufacturers industry median of 15.46. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current EV-to-EBIT is 13.17 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
EV-to-EBIT: 13.17 (13% above median its 10-year median of 11.63)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 14.8% below the Drug Manufacturers median (#297 of 690)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
